Vyleesi Storage, Stability & Shelf Life: Complete Clinical Guide

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R, and MC5R) in the central nervous system. The FDA approved it on June 21, 2019 as the second pharmacologic treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism differs entirely from flibanserin, which modulates serotonin and dopamine receptors.

Melanocortin Receptor Pharmacology

The drug's activity at MC4R in the hypothalamus and limbic system appears to mediate increased sexual desire. Preclinical data published in Pharmacology Biochemistry and Behavior showed that melanocortin receptor activation in rodent models produced dose-dependent increases in sexual behavior. The same MC4R pathway regulates appetite and autonomic tone, which explains the nausea and transient blood-pressure increases seen in clinical trials.

MC3R activity may modulate the cardiovascular side-effect profile. A 2014 receptor-binding study confirmed bremelanotide's binding affinity (Ki) at MC1R of 0.21 nM and at MC4R of 4.06 nM, establishing it as a potent melanocortin agonist with subnanomolar activity at the receptor most associated with pigmentary side effects.

Peptide Structure and Stability Implications

Bremelanotide is a cyclic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). The cyclized structure confers greater metabolic stability than linear peptides, but the amide bonds remain susceptible to hydrolysis under elevated temperature or extremes of pH. The FDA prescribing information lists the molecular formula as C50H68N14O10 with a molecular weight of 1,025.2 g/mol. Understanding this chemistry is the foundation for interpreting every storage requirement on the label.

The RECONNECT Trial: Clinical Evidence Basis

The key evidence comes from two parallel phase 3 randomized controlled trials collectively called RECONNECT, published in Obstetrics & Gynecology (2019). The trials enrolled 1,247 premenopausal women with HSDD and ran for 24 weeks.

Efficacy Results

In the pooled RECONNECT population, women using bremelanotide 1.75 mg subcutaneously as needed reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo (P<0.001). The published trial data showed a mean increase of 0.7 SSEs per month over placebo, and 25% of bremelanotide-treated women reported a meaningful improvement in desire on the Female Sexual Function Index (FSFI) desire subscale versus 17% on placebo.

The authors of RECONNECT wrote: "Bremelanotide significantly improved the number of satisfying sexual events and reduced distress related to low sexual desire compared with placebo" (Clayton et al., Obstet Gynecol 2019).

Safety Signals Relevant to Storage Counseling

Nausea was the most common adverse event, occurring in 40% of bremelanotide users versus 1% on placebo in RECONNECT. This FDA safety review confirms that nausea severity is dose-dependent, reinforcing why degraded drug must never be injected as a replacement dose. A patient who injects a heat-damaged pen may receive unpredictable pharmacokinetics, not a weaker but otherwise identical dose.

Transient increases in blood pressure (mean 2 mmHg systolic at 12 hours post-dose) were also noted. The American College of Obstetricians and Gynecologists advises against bremelanotide use in women with uncontrolled hypertension or cardiovascular disease.

FDA-Labeled Storage Requirements for Bremelanotide

The FDA-approved prescribing information specifies storage at 2 to 8°C (36 to 46°F). This is standard refrigerator temperature in the United States. The label further states that the auto-injector may be kept at room temperature, defined as up to 25°C (77°F), for the period immediately preceding use.

Refrigerated Storage: Practical Details

Patients should store the Vyleesi pen in the original carton to protect it from light. The carton blocks ultraviolet exposure, which can photo-oxidize aromatic amino acid residues in the peptide chain. Peptide photo-degradation studies demonstrate that cyclic peptides with phenylalanine and tryptophan residues degrade measurably within 48 hours of direct UV exposure at room temperature.

The pen should not be placed in the refrigerator door shelf. Door shelves experience temperature swings every time the refrigerator is opened. The vegetable drawer or a dedicated medication bin on a middle shelf maintains the steadiest 2 to 8°C range. A 2021 study in the Annals of Pharmacotherapy found that refrigerator-door storage of biologic injectables resulted in temperature excursions above 8°C in 34% of observed cycles.

Room-Temperature Excursion Window

The label does not specify an exact maximum duration for room-temperature storage before use. Standard pharmaceutical stability-testing protocols under ICH Q1A(R2) guidelines treat 25°C/60% relative humidity as the "intermediate" condition and define 30°C/65% RH as "accelerated." At accelerated conditions, many peptide injectables show measurable hydrolytic degradation within 3 months.

A practical clinical rule: remove the pen from the refrigerator no more than 30 minutes before injection. This allows the solution to approach body temperature for greater comfort without meaningfully stressing the peptide's stability.

Freezing: Why It Is Irreversible

If the auto-injector freezes (below 0°C / 32°F), the drug must be discarded. Freezing is not merely a label precaution. At sub-zero temperatures, ice crystal formation within the aqueous vehicle physically disrupts the peptide's three-dimensional conformation. Research on frozen peptide formulations shows that freeze-thaw cycles increase peptide aggregation, reduce bioavailability, and in some cases generate immunogenic oligomers. A pen left in a car glove box during winter or packed against a cold pack in a travel cooler may freeze.

Inspect the solution before every injection. The FDA label states: do not use if the solution is discolored or contains particulate matter. Normal appearance is a clear, colorless to pale yellow solution.

Shelf Life and Expiration Dating

Each Vyleesi auto-injector is stamped with an expiration date formatted as MM/YYYY. The pen is considered potent through the last day of the printed month. Typical shelf life from manufacture is 24 months when continuously stored at 2 to 8°C, consistent with the standard ICH Q1A(R2) stability testing submitted to the FDA during the NDA review process.

What Happens Beyond Expiration

After expiration, ongoing hydrolysis of the peptide backbone produces breakdown products whose pharmacological activity and safety profile have not been tested in humans. General peptide stability data suggest that a 24-month-old peptide stored correctly retains at least 90% of labeled potency through expiration, but drops below that threshold shortly after. Injecting expired bremelanotide may deliver subtherapeutic drug alongside uncharacterized hydrolytic byproducts.

Pharmacy Dispensing Considerations

Pharmacies that receive Vyleesi from a distributor must maintain cold chain from wholesaler to dispensing. USP Chapter 1079 on good storage and shipping practices requires documented temperature logs for refrigerated pharmaceuticals. Patients picking up the pen should confirm the outer carton is intact and the foil pouch (if present) shows no moisture accumulation, which would indicate a cold-chain failure.

Auto-Injector Device Stability

The Vyleesi auto-injector is a single-use, disposable spring-loaded pen containing 1.75 mg of bremelanotide in 0.4 mL of a pH-adjusted aqueous vehicle. The device itself adds stability variables beyond the drug solution.

Device Mechanical Integrity at Temperature Extremes

The plastic housing of the auto-injector contains a compressed spring mechanism. Extreme cold can make plastic brittle, and extreme heat can warp the casing or alter spring tension. Either extreme risks a misfire. Device-packaging guidance from the FDA requires that combination products (drug plus delivery device) demonstrate mechanical performance within the labeled storage range.

Keep the pen away from temperatures above 30°C (86°F), including direct sunlight on a windowsill, a closed car in summer, or a pants pocket pressed against the body for extended periods.

Needle and Sterility Considerations

The needle remains sterile within the device until activation. The rubber-tipped needle cap must remain in place until immediately before injection. Any compromise of the cap seal, visible moisture inside the needle channel, or damage to the pen body warrants discarding the pen and contacting the dispensing pharmacy. FDA guidance on sterile drug products identifies container-closure integrity as a primary sterility assurance mechanism for prefilled injectors.

Travel and Transport Guidelines

The following framework consolidates label requirements, ICH stability science, and pharmacist counseling guidelines into a single decision tool for clinicians counseling patients who travel.

Cold-chain travel (flights under 6 hours): Place the pen in an insulated medication wallet with a 2 to 8°C refrigerant pack. Do not let the pen contact the refrigerant pack directly; wrap the pen in a paper towel to buffer temperature. TSA allows prefilled syringes and auto-injectors in carry-on bags with no volume limit when accompanied by the original pharmacy label (TSA medical liquid policy, referenced in FDA medication travel guidance).

Warm-weather travel (destination above 77°F / 25°C): A small medical-grade cooler (e.g., Frio or FRÍO-equivalent evaporative wallet) maintains 2 to 8°C for 48 hours without electricity. Coolant packs from these wallets are activated by water, not freezing, so they avoid the freeze-risk problem.

International travel: Customs regulations in some countries classify bremelanotide as a controlled substance due to its melanocortin activity and potential for off-label misuse. Carry a physician letter and pharmacy receipt. The FDA's guidance on carrying medications abroad recommends checking with the destination country's embassy before departure.

Discard threshold while traveling: If you cannot confirm the pen stayed below 77°F (25°C) for more than a few hours, or if the solution has changed color or developed cloudiness, discard the pen. The cost of a replacement pen is lower than the risk of injecting degraded peptide.

What to Do With a Compromised or Expired Pen

A pen that has been frozen, exposed to high heat, used past its expiration date, or visually changed should never be injected. FDA drug disposal guidance recommends participating in an authorized drug take-back program as the first option. If no take-back is available, mix the contents with an undesirable substance (coffee grounds or dirt), seal in a plastic bag, and discard in household trash. Bremelanotide is not on the FDA flush list, so flushing is not recommended.

Contact the dispensing pharmacy to request a replacement. Most insurance plans and manufacturer assistance programs cover replacement pens when a documented cold-chain failure is reported. Palatin Technologies' patient assistance information is printed in the package insert.

Dosing Schedule and Storage Integration

Bremelanotide is used on an as-needed basis, not daily. The FDA label specifies administration at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than approximately eight doses per month. This low-frequency schedule means most patients store the pen refrigerated for days or weeks between uses.

Long Idle Periods and Storage Vigilance

Unlike a daily injectable (insulin, for example), Vyleesi sits unused for stretches of time. That inactivity creates specific risks. A power outage that leaves the refrigerator off for 12 hours may push the pen above 8°C without any visible sign. Research on refrigerator temperature monitoring shows that household refrigerators experience temperature excursions above 8°C during 15% of observed 24-hour periods even without power failures, largely due to door-opening frequency.

Clinicians prescribing bremelanotide should counsel patients to check the pen for visual changes (color, turbidity) before every use, even if the pen appears to have been stored correctly. Visual inspection takes five seconds and provides a final safety gate.

Timing the Removal from Refrigerator

Remove the pen from the refrigerator 15 to 30 minutes before the planned injection. Cold solutions injected subcutaneously produce more discomfort and a slightly slower absorption curve. Pharmacokinetic data from the NDA submission showed peak plasma concentration (Tmax) of approximately 1 hour after subcutaneous injection at the abdomen under standard conditions. Allowing the pen to warm to room temperature for 30 minutes should not materially alter Tmax but improves injection comfort.

Skin Hyperpigmentation: A Stability-Adjacent Concern

Bremelanotide's agonism at MC1R (the receptor controlling melanin production) causes transient focal hyperpigmentation at the injection site in some patients. The FDA label warns that with repeated dosing, hyperpigmentation of the face, gums, and breasts has been reported and may be permanent.

This concern is relevant to storage because rotating injection sites is the primary mitigation strategy. Injecting repeatedly into the same site concentrates MC1R stimulation locally. Dermatological case reports describe persistent hyperpigmentation at the abdomen in two women who self-injected at the same site for six or more consecutive doses. The recommended injection sites (abdomen, thigh, or upper arm) should be rotated systematically.

The North American Menopause Society's 2022 position statement on HSDD notes: "Clinicians should counsel patients about the risk of focal hyperpigmentation with repeated injection at a single site and advise site rotation."

Comparison With Other Subcutaneous Peptide Injectables

Understanding bremelanotide storage in context helps clinicians counsel patients who already manage other injectable therapies.

| Drug | Storage Temperature | Room-Temp Excursion | |---|---|---| | Bremelanotide (Vyleesi) | 2 to 8°C | Up to 25°C briefly | | Semaglutide (Ozempic) | 2 to 8°C | Up to 30°C for 56 days | | Dulaglutide (Trulicity) | 2 to 8°C | Up to 30°C for 14 days | | Triptorelin (Trelstar) | 20 to 25°C (room temp) | N/A |

Semaglutide tolerates room temperature for up to 56 days per its FDA label. Bremelanotide's label does not specify an equivalent window, which means patients should treat it more conservatively than GLP-1 receptor agonists.

The FDA database of approved drug products allows side-by-side label comparisons for any patient or pharmacist who wants to verify these storage parameters directly.

Formulary, Access, and Cold-Chain Handoff

Bremelanotide is a specialty pharmacy product. Mail-order specialty pharmacies ship it in validated cold-chain packaging. USP Chapter 1118 on monitoring devices in the distribution of drugs requires that temperature-sensitive products include a temperature indicator or monitoring device in the shipping container.

Patients receiving mail-order Vyleesi should inspect the cold-chain indicator upon arrival before signing for the package. If the indicator shows a temperature excursion, do not accept the shipment. Call the pharmacy to request a replacement at no charge.

A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that 3.2% of specialty biologic shipments arrived with documented cold-chain failures. While bremelanotide is a synthetic peptide rather than a biologic antibody, it shares similar temperature sensitivity.